18 completed, 6 active not recruiting, 3 recruiting, 3 terminated. 33 Phase 3, 2 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 33 | Completed 18, Active not recruiting 6, Recruiting 3, Terminated 3, Unknown 2, Not yet recruiting 1 |
| Phase 2 | 2 | Completed 1, Terminated 1 |
Follow Thrombocytosis: new trials by email Literature Review of Thrombocytosis trials Research Report on Thrombocytosis
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Phase 3 Study of INCA033989 Versus Best Available Therapy in Participants With Essential Thrombocythemia INCA033989, Best Available Treatment - Essential Thrombocythemia | Phase 3 | Recruiting | Incyte Corporation | 426 | 2026-09-08 | 2026-10-30 |
| Platelet Transfusion in Critically Ill Patients With Thrombocytopenia Platelet transfusion if platelet count ≤ 10 G/L, Platelet transfusion when platelet count ≤ 20 G/L - Thrombocythemia | Phase 3 | Not yet recruiting | Assistance Publique - Hôpitaux de Paris | 536 | 2024-11-01 | 2024-09-19 |
| Bomedemstat vs Hydroxyurea for Essential Thrombocythemia (MK-3543-007) Bomedemstat, Hydroxyurea, Bomedemstat placebo - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 300 | 2024-07-16 | 2026-08-27 |
| A Study to Evaluate Safety and Efficacy of Bomedemstat (MK-3543-017) Bomedemstat - Thrombocythemia, Essential, Primary Myelofibrosis | Phase 3 | Recruiting | Merck Sharp & Dohme LLC | 400 | 2024-05-23 | 2026-04-02 |
| A Study of Bomedemstat (IMG-7289/MK-3543) Compared to Best Available Therapy (BAT) in Participants With Essential Thrombocythemia and an Inadequate Response or Intolerance of Hydroxyurea (MK-3543-006) Bomedemstat, Anagrelide, Busulfan - Essential Thrombocythemia | Phase 3 | Active not recruiting | Merck Sharp & Dohme LLC | 340 | 2023-12-31 | 2026-10-02 |
| A Study to Evaluate the Efficacy and Safety of Ropeginterferon Alfa-2b in Essential Thrombocythaemia Patients Ropeginterferon alfa-2b (BESREMi®) - Essential Thrombocythaemia | Phase 3 | Active not recruiting | AOP Orphan Pharmaceuticals AG | 117 | 2023-12-04 | 2024-12-19 |
| A Study to Assess Efficacy, Safety, and Tolerability of P1101 in Adult Patients With PV P1101 (Ropeginterferon alfa-2b-njft), Ropeginterferon alfa-2b-njft (P1101) - Polycythemia Vera | Phase 3 | Active not recruiting | PharmaEssentia | 111 | 2022-10-26 | 2025-08-13 |
| AVAJAK: Apixaban/Rivaroxaban Versus Aspirin for Primary Prevention of Thrombo-embolic Complications in JAK2V617F-positive Myeloproliferative Neoplasms Direct Oral Anticoagulants, Low-dose aspirin - Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Recruiting | University Hospital, Brest | 1308 | 2022-07-13 | 2026-03-20 |
| A Study Comparing Imetelstat Versus Best Available Therapy for the Treatment of Intermediate-2 or High-risk Myelofibrosis (MF) Who Have Not Responded to Janus Kinase (JAK)-Inhibitor Treatment Imetelstat, Best Available Therapy (BAT) - Myelofibrosis | Phase 3 | Active not recruiting | Geron Corporation | 327 | 2021-04-12 | 2026-07-08 |
| Ropeginterferon Alfa-2b (P1101) vs. Anagrelide in Essential Thrombocythemia Patients With Hydroxyurea Resistance or Intolerance Ropeginterferon alfa-2b, Anagrelide - Essential Thrombocythemia | Phase 3 | Active not recruiting | PharmaEssentia | 174 | 2020-08-25 | 2026-07-22 |
| The Ruxolitinib Versus Best Available Therapy Trial in Patients With High Risk ET in Second Line Anagrelide, Ruxolitinib (JAKAVI®), IFNα/ PegIFNα - Essential Thrombocythemia | Phase 2 / Phase 3 | Terminated | French Innovative Leukemia Organisation | 13 | 2017-01-03 | 2021-06-29 |
| Hydroxyurea Versus Aspirin and Hydroxyurea in Essential Thrombocythemia Aspirin therapy interruption, Usual treatment by aspirin 100 mg/d in the active comparator arm, No interruption of aspirin in the Observational arm - MPN, Essential Thrombocythemia | Phase 3 | Unknown | Assistance Publique - Hôpitaux de Paris | 2250 | 2016-03-10 | 2017-07-26 |
| Pacritinib Versus Best Available Therapy to Treat Patients With Myelofibrosis and Thrombocytopenia Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 311 | 2014-02-01 | 2021-11-18 |
| Anagrelide Retard in Essential Thrombocythemia Anagrelide retard, Thromboreductin - Essential Thrombocythemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 106 | 2014-02-01 | 2015-07-29 |
| Pacritinib Versus Best Available Therapy to Treat Myelofibrosis Pacritinib, Best Available Therapy - Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis | Phase 3 | Terminated | CTI BioPharma | 327 | 2013-01-01 | 2020-09-29 |
| A Study of Low Dose Interferon Alpha Versus Hydroxyurea in Treatment of Chronic Myeloid Neoplasms PegIntron, Pegasys, Hydrea - Polycythemia Vera, Essential Thrombocythemia | Phase 3 | Completed | Thomas Stauffer Larsen | 202 | 2012-01-01 | 2022-04-27 |
| Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea in Polycythemia Vera (PV) and Essential Thrombocythemia (ET) PEGASYS, Hydroxyurea, Aspirin - High Risk Polycythemia Vera, High Risk Essential Thrombocythemia | Phase 3 | Completed | Ronald Hoffman | 168 | 2011-09-01 | 2019-04-30 |
| Anagrelide Retard vs. Placebo: Efficacy and Safety in "At-risk" Patients With Essential Thrombocythaemia Anagrelide retard, Placebo - Essential Thrombocythaemia | Phase 3 | Completed | AOP Orphan Pharmaceuticals AG | 146 | 2010-12-01 | 2016-05-26 |
| Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia SPD422 (anagrelide hydrochloride) - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 41 | 2010-10-27 | 2021-06-09 |
| Effect of SPD422 on Platelet Lowering and Safety in Japanese Adults With At Risk Essential Thrombocythaemia Anagrelide Hydrochloride - Essential Thrombocythemia (ET) | Phase 3 | Completed | Shire | 53 | 2010-10-27 | 2021-06-09 |
Showing 20 of 33. Sign in to see all of them.
Thrombocythemia, Essential (31) · Polycythemia Vera (18) · Primary Myelofibrosis (18) · Myeloproliferative Disorders (15) · Blast Crisis (12) · Burkitt Lymphoma (12) · Immunoblastic Lymphadenopathy (12) · Leukemia, Lymphocytic, Chronic, B-Cell (12) · Leukemia, Myeloid, Accelerated Phase (12) · Leukemia, Myeloid, Acute (12) · Leukemia, Myeloid, Chronic-Phase (12) · Lymphoma, B-Cell, Marginal Zone (12) · Lymphoma, Follicular (12) · Lymphoma, Large B-Cell, Diffuse (12) · Lymphoma, Large-Cell, Anaplastic (12)
Blood Platelet Disorders (33) · Hemic and Lymphatic Diseases (33) · Blood Coagulation Disorders (31) · Bone Marrow Diseases (31) · Hematologic Diseases (31) · Hemorrhagic Disorders (30) · Neoplasms by Site (19) · Bone Marrow Neoplasms (18) · Hematologic Neoplasms (18) · Myeloproliferative Disorders (18) · Pathological Conditions, Signs and Symptoms (15) · Neoplasms (14) · Cardiovascular Diseases (13) · Pathologic Processes (13)
anagrelide (7) · Hydroxyurea (4) · bomedemstat (3) · peginterferon alfa-2a (3) · 11-(2-pyrrolidin-1-ylethoxy)-14,19-dioxa-5,7,26-triazatetracyclo(19.3.1.1(2,6).1(8,12))heptacosa-1(25),2(26),3,5,8,10,12(27),16,21,23-decaene (2) · Aspirin (2) · Busulfan (2) · Early Intervention, Educational (2) · liposomal amphotericin B (2) · ruxolitinib (2) · Antilymphocyte Serum (1) · Asian ginseng (1) · Carboplatin (1) · Caspofungin (1) · Cyclophosphamide (1)
AOP Orphan Pharmaceuticals AG (4) · Merck Sharp & Dohme LLC (3) · Alliance for Clinical Trials in Oncology (2) · Assistance Publique - Hôpitaux de Paris (2) · CTI BioPharma (2) · Memorial Sloan Kettering Cancer Center (2) · PharmaEssentia (2) · Shire (2) · Case Comprehensive Cancer Center (1) · European Organisation for Research and Treatment of Cancer - EORTC (1) · French Innovative Leukemia Organisation (1) · Geron Corporation (1) · INSYS Therapeutics Inc (1) · Incyte Corporation (1) · Jonsson Comprehensive Cancer Center (1)
United States (19) · France (13) · Italy (10) · Germany (9) · Hungary (9) · United Kingdom (9) · Poland (8) · Australia (7) · Austria (7) · Canada (7) · Belgium (6) · Czechia (6) · Japan (6) · Spain (6) · Netherlands (5)
Barbara Grohmann-Izay, MD (1) · Barry J.A. Laird, MD (1) · Beth Ziemba (1) · Claire Harrison, MD (1) · Craig Zimmerman, PhD (1) · David J. Straus, MD (1) · Debra Barton, RN, PhD, AOCN, FAAN (1) · Eduardo Bruera, MD (1) · Heinz Gisslinger, Prof., MD (1) · Jean-Jacques Kiladjian, MD (1) · Joe Eid (1) · John A. Glaspy, MD, MPH (1)
PMID 33275766, PMID 15459300, PMID 17397698, PMID 22480131, PMID 23315161, PMID 25160063, PMID 26700120, PMID 26700123, PMID 27020837, PMID 30121892, PMID 31515250, PMID 34551507, PMID 35007321, PMID 35510486, PMID 35924546, PMID 36999619, PMID 39400386, PMID 40775758, PMID 41193116, PMID 42316774, PMID 42588744, PMID 42751490
2023 (4), P01CA108671 (1), P30CA068485 (1), R01CA127655 (1)